In your view, what impact should, and will, the LEADER trial have on clinical management of patients with T2D, especially those at risk for cardiovascular disease?

In your view, what impact should, and will, the LEADER trial have on clinical management of patients with T2D, especially those at risk for cardiovascular disease?

In your view, what impact should, and will, the LEADER trial have on clinical management of patients with T2D, especially those at risk for cardiovascular disease?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Lawrence Leiter, MD, FRCP(C), FACP

Lawrence Leiter, MD, FRCP(C), FACP

Head, Division of Endocrinology and Metabolism Director, Lipid Clinic Associate Director, Clinical Nutrition and Risk Factor Modification Centre St. Michael’s Hospital Professor of Medicine and Nutritional Sciences University of Toronto Toronto, Ontario